Home » Stocks » DMTK

DermTech, Inc. (DMTK)

Stock Price: $39.00 USD -0.67 (-1.69%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $39.51 +0.51 (1.31%) Jan 15, 7:55 PM
Market Cap 991.38M
Revenue (ttm) 5.35M
Net Income (ttm) -30.92M
Shares Out 18.93M
EPS (ttm) -3.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $39.00
Previous Close $39.67
Change ($) -0.67
Change (%) -1.69%
Day's Open 39.74
Day's Range 38.04 - 41.44
Day's Volume 704,190
52-Week Range 8.98 - 41.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 17 hours ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...

Other stocks mentioned: CAG, ALDX, FATE, GBIO, MRSN, ORI, REVG, RILY, SPT, YORW
Business Wire - 2 days ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN has...

Business Wire - 4 days ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that non-inva...

Business Wire - 5 days ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the closing o...

Business Wire - 1 week ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pricing o...

Business Wire - 1 week ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it has c...

Business Wire - 1 week ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointme...

The Motley Fool - 1 week ago

The biotech's skin cancer diagnostic tool is a significant improvement over the standard of care.

The Motley Fool - 2 weeks ago

The company's genomic test for melanoma won another positive coverage decision.

Business Wire - 2 weeks ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that Geisinge...

Business Wire - 2 weeks ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ:DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech ...

Zacks Investment Research - 2 weeks ago

DermTech (DMTK) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

The Motley Fool - 3 weeks ago

No news was good news.

Seeking Alpha - 3 weeks ago

DermTech's PLA stickers can help to diagnose melanoma despite being lower cost, more accurate, and less invasive compared to standard surgical biopsies.With 4-4.5mil surgical biopsies per year...

Business Wire - 4 weeks ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline r...

Business Wire - 1 month ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its inclusion...

Business Wire - 1 month ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entere...

Business Wire - 1 month ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the presentat...

Business Wire - 1 month ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entere...

Business Wire - 1 month ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech Presents New Clinical Research Abstract at the 2020 Fall Clinical Dermatology Conference

The Motley Fool - 2 months ago

Great things appear to be in store for these rising stars.

Other stocks mentioned: IIPR, TRUP
Seeking Alpha - 2 months ago

DermTech, Inc. (DMTK) CEO John Dobak on Q3 Results - Earnings Call Transcript

Business Wire - 2 months ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited fina...

Business Wire - 2 months ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced to...

Business Wire - 2 months ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech to Announce Third Quarter 2020 Financial Results on November 10, 2020

The Motley Fool - 2 months ago

Discover how these three companies could change the face of healthcare.

Other stocks mentioned: SMLR, TRUP
Business Wire - 4 months ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech Announces Appointment of Chief Scientific Officer

Business Wire - 4 months ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech to Participate in Upcoming Investor Conferences

Business Wire - 5 months ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc.

Business Wire - 6 months ago

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that as part ...

Forbes - 7 months ago

This week has been a successful one for markets, with the S&P 500 entering positive territory on the year. If you’re looking to hedge the rally, our deep learning algorithms have identified se...

Other stocks mentioned: BLNK, COCP, TTPH
Benzinga - 1 year ago

Shares of precision dermatology company DermTech Inc (NASDAQ: DMTK) are rallying Thursday after receiving Medicare coverage for its diagnostic test to rule out skin cancer.

About DMTK

DermTech, a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The comp... [Read more...]

Industry
Diagnostics & Research
CEO
Dr. John D. Dobak
Employees
60
Stock Exchange
NASDAQ
Ticker Symbol
DMTK
Full Company Profile

Financial Performance

In 2019, DermTech's revenue was $3.36 million, an increase of 37.76% compared to the previous year's $2.44 million. Losses were -$19.69 million, 96.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for DermTech stock is "Strong Buy." The 12-month stock price forecast is 36.33, which is a decrease of -6.85% from the latest price.

Price Target
$36.33
(-6.85% downside)
Analyst Consensus: Strong Buy